For CLL patients, the best care often comes from clinical trials, but unequal access limits opportunity and reduces diversity in research studies.
CLL Society has actively promoted equitable access in chronic lymphocytic leukemia trials and researched what factors determine the patient’s choice to enroll.
Dr. Adam Kittai, a member of CLL Society’s Medical Advisory Board who has extensively researched and published on issues related to diversity in CLL care and outcomes, and Dr. Brian Koffman, CLL Society’s Chief Medical Officer Emeritus were interviewed for this article: Why Diversity in CLL Clinical Trials Is Essential for Better Patient Outcomes.
In the article, they share valuable insights from that they learned their research and experience.